Skip to main content

Advertisement

SpringerLink
Log in

Is average adherence to HIV antiretroviral therapy enough?

  • Editorials
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;756–65.

  2. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–66.

    Article  PubMed  CAS  Google Scholar 

  3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    PubMed  CAS  Google Scholar 

  4. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700–5.

    Article  PubMed  CAS  Google Scholar 

  5. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417–23.

    Article  PubMed  CAS  Google Scholar 

  6. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968–77.

    PubMed  CAS  Google Scholar 

  7. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–17.

    Article  PubMed  CAS  Google Scholar 

  8. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–83.

    Article  PubMed  CAS  Google Scholar 

  9. Altice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med. 1998;129:503–5.

    PubMed  CAS  Google Scholar 

  10. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–6.

    Article  PubMed  CAS  Google Scholar 

  11. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–7.

    Article  PubMed  CAS  Google Scholar 

  12. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30:278–87.

    PubMed  CAS  Google Scholar 

  13. Howard A, Arnsten J, Gardner L, et al. Lack of multi-drug resistance in nonresponders to antiretroviral therapy with poor adherence. Presented at the First International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8–11, 2001.

  14. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 2001;15:1701–6.

    Article  PubMed  CAS  Google Scholar 

  15. Bangsberg D, Charlebois E, Grant R, et al. Low levels of adherence do not increase risk of HIV drug resistance. Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002.

  16. Bangsberg DR, Kagay CR, Porco T, et al. Modeling the relationship between adherence and accumulation of protease inhibitor drug resistance mutations based on objectively measured adherence and empirically derived relationships. Presented at the Eleventh HIV Drug Resistance Workshop, Seville, July 2–5, 2002.

  17. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26(suppl):25–33.

    Article  Google Scholar 

  18. Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001.

  19. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863–8.

    CAS  Google Scholar 

  20. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401–10.

    PubMed  CAS  Google Scholar 

  21. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control; 2002.

    Google Scholar 

  22. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.

    Article  PubMed  CAS  Google Scholar 

  23. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051–8.

    Article  PubMed  Google Scholar 

  24. deOlalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla J. Impact of adherence on highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;30:105–10.

    Google Scholar 

  25. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472–80.

    Article  PubMed  CAS  Google Scholar 

  26. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance A. Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis. 2001;1009–16.

  27. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001;7:712–8.

    Article  PubMed  CAS  Google Scholar 

  28. Deeks SG, Hoh R, Grant RM, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002;185:315–23.

    Article  PubMed  CAS  Google Scholar 

  29. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946–53.

    Article  PubMed  CAS  Google Scholar 

  30. Cainelli F, Vento S. Full adherence to HAART: is it really necessary? Arch Intern Med. 2002;162:944–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, UCSF, USA

    David R. Bangsberg MD, MPH

  2. Positive Health Program, San Francisco General Hospital, UCSF, USA

    David R. Bangsberg MD, MPH

  3. Positive Health Program, San Francisco General Hospital, UCSF, San Francisco, Calif

    Steven G. Deeks MD

Authors
  1. David R. Bangsberg MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven G. Deeks MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bangsberg, D.R., Deeks, S.G. Is average adherence to HIV antiretroviral therapy enough?. J GEN INTERN MED 17, 812–813 (2002). https://doi.org/10.1046/j.1525-1497.2002.20812.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.2002.20812.x

Search

Navigation